Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 11,257 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Newborn Clear all

Conditions: Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia
Interventions: vorinostat, gemtuzumab ozogamicin, azacitidine; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 50 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 4
States / cities: Stanford, California • Bremerton, Washington • Seattle, Washington

Conditions: Heart Defects, Congenital
Interventions: nesiritide, milrinone, placebo; Drug
Lead sponsor: John M Costello; Other
Eligibility: Not listed
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Fractures, Bone, Deformity; Bone
Interventions: A treatment group that will watch a non-VR video via an iPad, A treatment group that will have headset on and will watch a non-VR video, A treatment group that will be immersed in the VR game (Bear Blast) via the headset.; Device
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 4 Years to 14 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Dravet Syndrome (DS), Lennox Gastaut Syndrome (LGS)
Interventions: Soticlestat; Drug
Lead sponsor: Takeda; Industry
Eligibility: 2 Years to 56 Years
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 26
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 19 more

Conditions: Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica Dominans
Interventions: Not listed
Lead sponsor: Krystal Biotech, Inc.; Industry
Eligibility: 6 Months and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Williams Syndrome
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 14 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hereditary Diseases
Interventions: Audiotaped Focus Group, Demographic Questionnaire, Audiotaped Interview, WAMMI Inventory; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Respiratory Distress Syndrome, Newborn, Premature Birth
Interventions: Poractant Alfa; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: Up to 15 Minutes
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Duchenne Muscular Dystrophy
Interventions: Wearable Device, Duchenne Video Assessment (DVA); Device · Other
Lead sponsor: Solid Biosciences Inc.; Industry
Eligibility: 4 Years to 12 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma, Central Nervous System Neoplasm, Childhood Clear Cell Sarcoma of Soft Tissue, Clear Cell Sarcoma of Soft Tissue, Ewing Sarcoma, Hepatoblastoma, Hepatocellular Carcinoma, Osteosarcoma, Recurrent Adrenal Cortical Carcinoma, Recurrent Alveolar Soft Part Sarcoma, Recurrent Clear Cell Sarcoma of Soft Tissue, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Hepatocellular Carcinoma, Recurrent Kidney Wilms Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Recurrent Primary Malignant Central Nervous System Neoplasm, Recurrent Renal Cell Carcinoma, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Thyroid Gland Medullary Carcinoma, Refractory Adrenal Cortical Carcinoma, Refractory Alveolar Soft Part Sarcoma, Refractory Clear Cell Sarcoma of Soft Tissue, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Hepatocellular Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Osteosarcoma, Refractory Primary Central Nervous System Neoplasm, Refractory Primary Malignant Central Nervous System Neoplasm, Refractory Renal Cell Carcinoma, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory Thyroid Gland Medullary Carcinoma, Refractory Wilms Tumor, Renal Cell Carcinoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Solid Neoplasm, Thyroid Gland Medullary Carcinoma, Wilms Tumor
Interventions: Cabozantinib, Cabozantinib S-malate, Pharmacological Study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years to 30 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 142
States / cities: Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 104 more

Conditions: Skin Laxity
Interventions: Ulthera System Treatment; Device
Lead sponsor: Ulthera, Inc; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Mesa, Arizona

Conditions: Autosomal Dominant Polycystic Kidney Disease
Interventions: Not listed
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Hereditary Malignant Neoplasm, Hereditary Neoplastic Syndrome
Interventions: Communication Intervention, Health Promotion and Education, Informational Intervention, Survey Administration; Other
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 625 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: MPS IVA, MPS VI
Interventions: Vosoritide Injection [Voxzogo]; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 5 Years to 10 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Oakland, California

Conditions: Hereditary Hemorrhagic Telangiectasia
Interventions: Not listed
Lead sponsor: Unity Health Toronto; Other
Eligibility: Not listed
Enrollment: 2,272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2025
U.S. locations: 14
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 11 more

Conditions: Duchenne Muscular Dystrophy (DMD)
Interventions: Prednisone, Placebo; Drug
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 3 Years to 6 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Puberty, Hyperandrogenism
Interventions: Micronized progesterone suspension, Placebo; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 10 Years to 17 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Lactose Intolerance
Interventions: Lactobacillus acidophilus MPH734, Placebo; Dietary Supplement
Lead sponsor: Lemuel W. Taylor IV; Other
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Belton, Texas

Conditions: Sickle Cell Disease
Interventions: GBT021601; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Miami, Florida • Atlanta, Georgia

Conditions: Pain
Interventions: bupivicaine epidural, bupivicaine epidural infusion patient epidural, bupivicaine; Drug
Lead sponsor: MemorialCare; Other
Eligibility: 18 Years and older · Female only
Enrollment: 270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Hereditary Angioedema
Interventions: Ruconest; Biological
Lead sponsor: Bernstein Clinical Research Center; Other
Eligibility: 14 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Birmingham, Alabama • Cincinnati, Ohio

Conditions: Hurler Syndrome, Inherited Metabolic Disorder, Lysosomal Storage Disorder, Metachromatic Leukodystrophy, Inborn Errors of Metabolism
Interventions: rivogenlecleucel, rimiducid; Biological · Drug
Lead sponsor: Bellicum Pharmaceuticals; Industry
Eligibility: 3 Months to 21 Years
U.S. locations: 2
States / cities: Los Angeles, California • Palo Alto, California

Conditions: Huntington Disease
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 4
States / cities: Baltimore, Maryland • Bethesda, Maryland • Pittsburgh, Pennsylvania + 1 more

Conditions: Cystic Fibrosis, Contraception, Physician-Patient Relations, Pregnancy Complications
Interventions: MyVoice:CF; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML

Effects of Perioperative Nesiritide or Milrinone Infusion on Recovery From Fontan Surgery

Virtual Reality Distraction During Outpatient Pediatric Orthopedic Procedures

A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome

A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)

Fat Distribution and Glucose Metabolism in Williams Syndrome

A Social Media Approach to Improve Genetic Risk Communication Phase I

Prophylactic Minimally Invasive Surfactant Evaluation

Evaluation of Home Based Assessments on Participants With DMD

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Treatment of the Face and Neck With Lower Ulthera System Energy Settings

Autosomal Dominant Polycystic Kidney Disease Somatic Mutation Biorepository

Navigation Interventions to Improve Cascade Genetic Testing Among Relatives of Patients With Hereditary Cancer Syndromes

Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VI

Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia

A Trial of Chronotherapy of Corticosteroids in Duchenne Muscular Dystrophy

Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

Does Daily Supplementation of Lactobacillus Acidophilus MPH734, for One Week, Affect Acute (Immediate), Subacute (7 Days), and Post-treatment Discontinuation Lactose Metabolism, Gastrointestinal Symptoms, and Clinical Markers of Inflammation and Safety Compared to a Placebo

A Study to Evaluate GBT021601-012 Single Dose and Multiple Dose in Participants With Sickle Cell Disease (SCD)

Patient Controlled Epidural Analgesia Versus Continuous Epidural Infusion: Obstetrical and Neonatal Outcomes

Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest)

BPX-501 T Cells Infused Post Stem Cell Transplant in Pediatrics With Non-Malignant Disorders Ineligible for BPU004 Study

Making Sense of a Positive Genetic Test Result for Huntington Disease

MyVoice:CF Decision Aid for Women With Cystic Fibrosis